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The protection from ischaemia‐reperfusion‐associated myocardial infarction worsen-
ing remains a big challenge. We produced a bioartificial 3D cardiac patch with
cardioinductive properties on stem cells. Its multilayer structure was functionalised
with clinically relevant doses of adenosine. We report here the first study on the
potential of these cardiac patches in the controlled delivery of adenosine into the
in vivo ischaemic‐reperfused pig heart. A Fourier transform infrared chemical imaging
approach allowed us to perform a characterisation, complementary to the histological
and biochemical analyses on myocardial samples after in vivo patch implantation,
increasing the number of investigations and results on the restricted number of pigs
(n = 4) employed in this feasibility step. In vitro tests suggested that adenosine was
completely released by a functionalised patch, a data that was confirmed in vivo after
24 hr from patch implantation. Moreover, the adenosine‐loaded patch enabled a
targeted delivery of the drug to the ischaemic‐reperfused area of the heart, as
highlighted by the activation of the pro‐survival signalling reperfusion injury salvage
kinases pathway. At 3 months, though limited to one animal, the used methods
provided a picture of a tissue in dynamic conditions, associated to the biosynthesis
of new collagen and to a non‐fibrotic outcome of the healing process underway.
The synergistic effect between the functionalised 3D cardiac patch and adenosine
cardioprotection might represent a promising innovation in the treatment of
reperfusion injury. As this is a feasibility study, the clinical implications of our findings
will require further in vivo investigation on larger numbers of ischaemic‐reperfused
pig hearts.
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1254 CRISTALLINI ET AL.1 | INTRODUCTION
Ischaemic heart disease is the leading cause of death in the human
population (Gaziano, Bitton, Anand, Abrahams‐Gessel, & Murphy,
2009) and the protection against ischaemia‐reperfusion (I/R) damage
and myocardial infarction (MI) remains a challenge (Pagliaro & Penna,
2014; Yellon & Hausenloy, 2007).
Despite decades of impressive improvements in therapies for
patients developing MI, the current therapies do not fully restore the
functionality of the damaged myocardial tissue. Paradoxically, about
50% of the myocardium damage after MI is a result of the rapid re‐
oxygenation of the tissues, known as reperfusion injury (Hausenloy
& Yellon, 2008). Reperfusion injury therefore remains a major problem
in the treatment of MI patients.
Ischaemic postconditioning, consisting in brief repetitive ischaemic
episodes during early reperfusion (Galagudza, Kurapeev, Minasian,
Valen, & Vaage, 2004; Zhao, 2010), displays infarct‐sparing effect,
which can also be achieved by administration of cardioprotective
drugs at the time of the myocardial reperfusion or just prior to it
(Galagudza, Blokhin, Shmonin, & Mischenko, 2008; Pagliaro & Penna,
2014). Among the pharmacological agents used to induce protection
are included adenosine, anaesthetics, cyclosporin‐A, NO donors, and
P2Y12 inhibitors, administered mostly through intracoronary or intra-
venous infusion (Hausenloy et al., 2017; Pagliaro, Femminò, Popara, &
Penna, 2018). This pharmacological postconditioning focuses on
attenuating the mitochondrial permeability and on promoting the
activity of reperfusion injury salvage kinases (RISK), including
extracellular‐regulated kinase (ERK) and the serine/threonine kinase
Akt (Yellon & Hausenloy, 2007).
However, the postconditioning translation into clinical practice has
so far been disappointing. Moreover, the pharmacological agents sug-
gested for infarct size limitation have serious side effects when used
at cardioprotective doses, which further hinders their clinical use
(Pagliaro & Penna, 2014; Sanada, Komuro, & Kitakaze, 2011). One
solution to the problem might be a timely and direct delivery of the
cardioprotective drugs into ischaemic‐reperfused myocardium, in
order to administer the drugs in a sufficient concentration to achieve
the highest efficiency and limit the side effects (Ye & Yang, 2009).
There is now considerable evidence for adenosine involvement in
the mechanisms of cardiac protection from conditioning‐induced
ischaemia. In particular, by using adenosine and selective agonists
and antagonists of several adenosine receptors (Donato et al., 2007;
Norton, Jackson, Turner, Virmani, & Forman, 1992; Xi et al., 2009),
as well as genetic approaches (Morrison, Tan, Ledent, Mustafa, &
Hofmann, 2007; Xi et al., 2008), it has been clearly demonstrated that
adenosine and adenosine receptors activation plays a role of para-
mount importance in cardioprotection against ischaemia/reperfusion
myocardial injury. The current thought is that all the adenosine recep-
tors are needed and interact to produce cardioprotection (Lasley,
Kristo, Keith, & Mentzer, 2007; Urmaliya, Pouton, Ledent, Short, &
White, 2010; Zhan, McIntosh, & Lasley, 2011). This point of viewstrongly supports the use of adenosine instead of a specific single
receptor agonist.
However, the clinical use of adenosine for myocardial protection
has yielded conflicting results and may be limited because of its heavy
side effects, such as hypotension and bradycardia (Marzilli, Orsini,
Maraccini, & Testa, 2000). It is therefore likely that the modality of
drug delivery may be crucial.
We recently produced bioartificial cardiac patches and demon-
strated their micropatterning‐mediated effect to guide and control
proliferation and differentiation of stem cells in cardiac sense
(Cristallini et al., 2014; Cristallini et al., 2016).
In this research, we investigated on a small number of pigs
(n = 4) the potentiality of multilayered Poly(lactic‐co‐glycolic acid)
(PLGA)/gelatine cardiac patches for the targeted delivery of adeno-
sine into the ischaemic‐reperfused large‐mammalian heart. The pri-
mary goal of this feasibility study was to compare the differences
between functionalised and nonfunctionalised patch. Although the
exact cardioprotective mechanisms of adenosine are not yet fully
understood, we studied the effects of adenosine on some
protective/prosurvival kinases (Ovize et al., 2010). The physico‐
chemical, degradative, and pharmacological characterisation of the
scaffolds was performed before and after implantation. Furthermore,
histomorphologic, biochemical, and spectroscopic analyses of the
explants were carried out, to verify the cardioprotective effect of
the adenosine‐loaded patch.2 | MATERIALS AND METHODS
2.1 | Adenosine delivery microstructured multilayer
patch (ADMMP) preparation
Our delivery cardiac patch involved the functionalisation with adeno-
sine of a microstructured bilayer based on PLGA (50:50, 40–75 kDa,
Sigma Aldrich, USA) and gelatine from porcine skin (gelatine A, Sigma
Aldrich, USA), prepared as already described (Cristallini et al., 2016;
Khademhosseini et al., 2007; Kim et al., 2012; Zong et al., 2005).
The functionalisation method with adenosine (>99%, Sigma Aldrich,
USA) was optimised (Figure 1a) in order to reach an immediate and
quantitatively elevated release of adenosine in a very short time, as
described in Supporting Information. Identical patches, but without
adenosine functionalisation, were also produced (MMP). The patches
were dried and sterilised according to a previously optimised method
(Rosellini, Cristallini, Barbani, Vozzi, & Giusti, 2009).2.2 | Experimental plan and surgical procedures
Four Large White × Landrace pigs (weight: 46 kg, aged 5 months,
sex: female) were utilised. The animals were treated in accordance
with the provisions of January 27th, 1992 No 116 Leg. Dec., imple-
mentation of Dir No. 86/609/EEC on the protection of animals used
FIGURE 1 (a) Scheme of ADMMP preparation; (b) release trend of adenosine from the sterilised final scaffold with adenosine loading (ADMMP).
SEM images of section and surface of ADMMP (c, d) before and (e, f) after release at 24 hr. The section image of ADMMP before release test
shows the thickness of the two microstructured external layers and the thickness of the internal layer containing gelatin and adenosine. The
section image after 24‐hr release in MilliQ water points out an intermediate empty space. The surface image of the scaffold shows the presence of
free voids, due to the dissolution of the gelatin and adenosine globular structures [Colour figure can be viewed at wileyonlinelibrary.com]
CRISTALLINI ET AL. 1255for experimental and other scientific purposes, art. 5 (a, b, c, d, e), and
Leg. Dec. N. 66, published in “Gazzetta Ufficiale della Repubblica
Italiana,” issue No 61, March 14th, 2014. In line with the EU Directive
2010/63/EU, the principle of the three Rs were implemented in
this work. Three animals were sacrificed after 24 hr from intervention
(1‐3_AMI) and one after 3 months of follow‐up (4_AMI) (Table 1).TABLE 1 Experimental plan for the in vivo characterisation of the patch
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the effect of adenosine on the acute myocardial infarct model, two
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(3_AMI + ADMMP). To evaluate patch bioabsorbance and preliminary
patch effect at a medium follow‐up, one pig was sacrificed at
3 months after the implantation of an adenosine‐loaded patch
(4_AMI + ADMMP). Details concerning surgical procedures and
bioptic sampling can be found in Supporting Information. In short,
a biopsy was performed 10 min before the LAD occlusion in the
area in which ischaemia would have later been induced. For all
biopsies, 14G disposable guillotine needles were used. The LAD
occlusion was performed by interrupting the anterior descending
coronary blood flow with a tourniquet. Five minutes after the LAD
ligature, the patch was sutured on the ischaemic area of the myocar-
dium and fixed with four stitches of 5.0 prolene. Two biopsies, one
in the ischaemic area and one in a remote area, were performed
45 min after LAD occlusion. After 50 min from the occlusion, the
tourniquet was released (LAD reopening, reperfusion step), and
10 min later, two myocardial biopsies, one in the ischaemic area
and one in a remote area, were performed. Finally, two additional
biopsies, one in the ischaemic area and one in a remote area, were
performed 60 min after LAD reopening; the surgical cut was then
sutured, and the animal was awakened. The animals were followed
daily to measure sensitive parameters such as sensorium, conjuncti-
val mucous membranes, body temperature, ventilation rhythm and
breathing rate, and heart rate. Daily dressing of surgical wounds
was performed. In the early days of follow‐up, the animal was kept
under drug therapy that included the use of morphine, analgesics
(FANS), and antibiotics.2.3 | Histomorphological analysis
After the animal sacrifice, the heart was explanted and analysed from
a macroscopic and microscopic point of view. The heart was
observed, and pictures were taken using a stereoscopic microscope
(Leica Z6 APO) to highlight the presence of macroscopic interactions
between the patch and the myocardium. At the end of the macro-
scopic examination, a sample of the myocardium underlying the patch
was taken for histological analysis, and a sample of the myocardium in
an area not interested by the ischaemic event was taken as a control.
The obtained samples were processed for paraffin embedding.
The samples were sliced in 4‐ to 5‐μm serial sections and stained with
haematoxylin/eosin (HE) and Gomori stains. The slides were observed
and photographed under a biological microscope (Nikon Eclipse
E600). Ten pictures per animal, at 40× magnification, were obtained
from the HE‐stained serial sections. The pictures were taken ran-
domly in the area immediately under the patch. The epicardial thick-
ness was measured using the image analysis software Image‐Pro
Premier 9.1 (Media Cybernetics). Ten linear measures were per-
formed on each sample (2_AMI + MMP, 3_AMI + ADMMP, and
4_AMI + ADMMP) and the epicardial thickness calculated as the
mean of the obtained values. Inflammatory cells (macrophages, eosin-
ophils, neutrophils, lymphocytes, and mastocytes) were distinguished
based on their morphology and dye affinities. The total cell numberand the inflammatory cell number were accurately counted using
the Image‐Pro Premier 9.1 software. Other samples, both underlying
the patch and in a remote area, were taken and frozen for physico‐
chemical analyses.2.4 | Biochemical study of the biopsies by means of
western blot analysis
Western blot was used to analyse the heart biopsies. Specific antibodies
against porcine total AKT (diluted 1:1000), phosphorylated Akt (diluted
1:1000), total ERK 1/2 (diluted 1:1000), phosphorylated ERK 1/2
(Diluted 1:500; all from Cell Signaling Technology, USA), and α‐actinin
(1:10000, Sigma‐Aldrich, USA) were used. Expression levels of
phospho‐AKT and phospho‐ERK 1/2 were normalised to both
α‐actinin and total AKT/total ERK proteins. For each animal, the expres-
sion levels of phospho‐AKT and phospho‐ERK proteins detected in the
biopsies, sampled after either LAD ligature or LAD reopening, were
normalised against the expression levels detected in the biopsies taken
before LAD ligature, to reduce intertest animal biological differences.2.5 | In vitro morphological, physico‐chemical, and
functional ADMMP characterisation before and after
apposition onto myocardium
Release tests of adenosine from ADMMP were performed by high‐
performance liquid chromatography (HPLC, Perkin Elmer Series
200) as described in Supporting Information. Morphological analyses
were carried out on gold sputtered samples by scanning electron
microscopy (SEM, Jeol JSM 5600). All the samples were lyophilised
before analysis. The chemical analysis was carried out by Fourier
transform infrared (FT‐IR) spectroscopy chemical imaging (Perkin
Elmer Spotlight 300). FTIR spectroscopy is well known as a sensitive
tool in identifying chemical structures of organic compounds, includ-
ing synthetic and biological polymers. In this study, FTIR technique
was used to evaluate both the chemical composition of patch and
possible alterations of protein conformation and nucleic acids in
the treated myocardial tissue.
The attenuated total reflectance (ATR) sampling technique was per-
formed on small fragments of ADMMP or on myocardial samples.
Spectral images were acquired in μATR mode (the spectral resolution
was 4 cm−1, and the spatial resolution was 100 × 100 μm). The spectra
were collected by putting in contact the ATR objective and the sample
and collecting the spectrum generated from the surface layer of the
sample. The obtained correlation map indicates the areas of each image
where the spectra are most similar to a reference spectrum. The band
ratio analysis involves the measurement of the band intensity or area
of an internal reference, with respect to that of a band of interest.
FT‐IR analysis was carried out directly on the patch detached from
2_AMI + ADMMP and 3_AMI + ADMMP tissues after 24 hr of follow‐
up. The analysis was not feasible on the patch from the
4_AMI + ADMMP tissue, because the patch was completely
reabsorbed after 3 months. A FT‐IR analysis was carried out on
CRISTALLINI ET AL. 1257myocardium samples both from the ischaemic area and remote areas
after 24 hr and 90 days of follow‐up. The myocardium samples under-
lying the patch were further sliced, obtaining closer (proximal) and
deeper (distal) sections respect to patch positioning. Before FT‐IR
analysis, all samples were lyophilised at the same temperature rate.
FT‐IR chemical imaging allows to gain information about the chem-
ical composition of healthy and diseased human tissues (Liu et al.,
1996; Liu, Dixon, & Mantsch, 1999); the most important parameters
to distinguish acute and chronic MI are reported in Table 2.3 | RESULTS
3.1 | In vitro characterisation of ADMMP before
implantation
After sterilisation, ADMMP was subjected to the in vitro release test
showing a high delivery in the interval from 1 min to 1 hr (Figure 1
b), corresponding to 43% with respect to the amount contained in
the device (17.6 ± 0.2 mg), in line with the doses of intraluminally
administered adenosine (Ross et al., 2005).
SEM images of ADMMP before and after adenosine release
(Figure 1c–f) and spectra obtained by FT‐IR chemical imaging con-
firmed that the adenosine was completely released as described in
Supporting Information.3.2 | Histomorphological analyses
The hearts were explanted at either 24 hr or 3 months follow‐up. The
explanted hearts were observed as intact (2_AMI + MMP,
3_AMI + ADMMP, and 4_AMI + ADMMP) or after accurate slicing
(1_AMI) by stereomicroscopy, to highlight possible alterations and/or
interactions between patch and cardiac tissue. No important macro-
scopic alterations were evidenced in the examined hearts; only some
areas of pericardial–epicardial adhesion, due to implant procedures,
was visible in all the explants. A well‐localised necrotic area was visible
in 1_AMI after LAD ligature; histology showed blood vessels necrosis,
vacuolisation, inflammatory cells infiltration, and degenerated red
blood cells (Figure 2a).TABLE 2 FT‐IR parameters in acute and chronic myocardial infarction (M
Acute MI C
Parameters Tissue correlation P





Reduction of C═O stretching
vibrations of: phospholipids
(1,738 cm−1)
nucleic acids (1,721 cm−1)
Loss of cellular components





Modification of protein secondary
structure
Modification of ECM proteins InThe patches appeared well adherent to the epicardial surface in
both 2_AMI + MMP and 3_AMI + ADMMP (24‐hr follow‐up); the
patch in 4_AMI + ADMMP, however, at 3‐month follow‐up, appeared
completely reabsorbed with only the stitches remaining visible
(Figure 2m). No tissue growth due to foreign body reaction was
detectable in any of the hearts.
The histological examination corroborated the macroscopic data.
Some thrombus depositions were visible on the outer surface of
2_AMI + MMP. A good adhesion of the patch to the underlying myo-
cardium was confirmed in the samples at 24‐hr follow‐up (Figure 2b).
A complete absorption of the patch in 4_AMI + ADMMP was also his-
tologically confirmed (Figure 2n). Further, the histological analysis
showed a moderate epicardial thickening; after morphometrical analy-
sis, it resulted in 0.692 ± .0.023 mm in the 24‐hr follow‐up samples
and in 0.797 ± 0.031 mm in the 3‐month follow‐up samples; as the
two data can be considered comparable, the epicardial thickening
could be ascribed to pericardium–epicardium adhesion.
Inflammatory cells were present in all the samples, though in vari-
able numbers: In 2_AMI + MMP, abundant inflammatory cells were
present under the epicardial surface and inside the myocardium
(Figure 2c–f); in 3_AMI + ADMMP and in 4_AMI + ADMMP, inflam-
matory cells were less abundant and localised only under the epicar-
dial layer (Figure 2i,j). This suggested a lower inflammation in the
animals in which the patch with adenosine (ADMMP) was implanted.
The histological analysis carried out on 4_AMI + ADMMP showed
the presence of unaltered cardiomyocytes together with areas of
myxoid tissue (Figure 2o,p). Although, in the 2_AMI + MMP samples,
large areas of heavily degenerated myocardial tissue with disarranged
myofibrillar structure of cardiomyocytes (Gomori‐stain; Figure 2g, h)
were visible, in 3_AMI + ADMMP, only limited areas of suffering, yet
not degenerated, myocardial tissue with preserved myofibrillar
structure of cardiomyocytes (Gomori stain) were present (Figure 2k,l).
Histomorphometrical analysis showed that the total cell number
was considerably higher in 2_AMI + MMP than 3_AMI + ADMMP,
and the number of inflammatory cells was, respectively, 62% and
38% of the total number. Furthermore, in 2_AMI + MMP,
mononucleates seemed to outnumber polymorphonucleates, whereas
in 3_AMI + ADMMP, most of the inflammatory cells were
polymorphonucleates, mostly eosinophils. All these findings suggested
protective effects of adenosine‐loaded patches.I)
hronic MI
arameters Tissue correlation
crease of the band intensity
at 1,082 cm−1 and at 1,662 cm−1
in the region of 31‐helix of collagen
Collagen deposition
ariation of the CH2/CH3 peak ratio
H2 at 2,852–2,926 cm
−1
H3 at 2,956 cm
−1
Reduction of the lipid
content respect to
collagen fibrotic tissue
crease of absorption at 1,638 cm−1
in a spectral region of collagen I triple helix
Fibrotic tissue
FIGURE 2 (a) A necrotic myocardium area in 1_AMI (HE 10×); (b) patch adhesion in 2_AMI + MMP. Red line shows the border between patch
(up) and epicardium (down) (HE 4×); (c) abundant inflammatory cells under the epicardial layer in 2_AMI + MMP (HE 20×); (d) abundant
inflammatory cells under the epicardial layer in 2_AMI + MMP. High magnification (HE 100×). The image shows the presence of macrophages
(red arrow) neutrophils (yellow arrow) and eosinophils (green arrow); (e) inflammatory cells inside the myocardium in 2_AMI + MMP (HE 20×); (f)
inflammatory cells inside the myocardium in 2_AMI + MMP. High magnification (HE 40×); (g) normal (on the left) and degenerated (on the right)
myocardium tissue in 2_AMI + MMP (HE 40×); (h) degenerated myocardium in 2_AMI + MMP (Gomori 40×); (i) inflammatory cells under the
epicardial layer in 3_AMI + ADMMP (HE 20×); (j) inflammatory cells under the epicardial layer in 3_AMI + ADMMP. High magnification (HE 100×).
The image shows the presence of macrophages (red arrow), neutrophils (yellow arrow), and lymphocytes (orange arrow); (k) suffering myocardium
in 3_AMI + ADMMP (HE 40×); (l) suffering myocardium in 3_AMI + ADMMP (Gomori 40×); (m) macroscopic image of the reabsorbed patch in
4_AMI + ADMMP; (n) microscopic image of the reabsorbed patch in 4_AMI + ADMMP (HE 20×); (o) normal myocardium in 4_AMI + ADMMP (HE
40×); (p) mixoid tissue in 4_AMI + ADMMP (HE 20×) [Colour figure can be viewed at wileyonlinelibrary.com]
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To dissect the putative mechanisms of the cardioprotective effects of
adenosine‐loaded patches, we quantified the RISK pathway activation
on the heart biopsies taken at 0–10‐60 min time course after LAD.
The left ventricular (LV) tissue from the non‐infarcted zone (remote
area biopsies) showed no change in phospho‐ERK and phospho‐AKT
expression (data not shown). However, if compared with the
2_AMI + MMP animal that did not show any significant signs of
activation, LV tissue sampled close to the ischaemic area from
3_AMI + ADMMP and 4_AMI + ADMMP showed RISK pathway
activation. An increase in AKT phosphorylation was highlighted in
3_AMI + ADMMP, even in the biopsy taken before LAD reopening
(time: 0 min, about 45 min from scaffold implantation; Figure 3a,c).
However, phospho‐AKT was not pointed out in the biopsies sampled
after LAD reopening in this condition. 4_AMI + ADMMP showed an
increase in ERK 1/2 phosphorylation in the biopsy taken before LAD
reopening, with a further increase in the biopsy taken 10 min after
LAD reopening (time: 10 min, Figure 3b,d). In both animals,the activation of the RISK pathway turned back to basal levels after
60 min from LAD reopening, as expected (time: 60 min, Figure 3).
These findings suggest that ADMMP implant before reperfusion
activates signalling pathways that protect against reperfusion injury
during MI.
3.4 | Physico‐chemical, degradative, and
pharmacological characterisation of the scaffolds after
explant
The results obtained by HPLC and FT‐IR on the patch at 24 hr of
follow‐up revealed no appreciable amounts of adenosine in agreement
with in vitro tests. The in vitro analysis carried out directly on the
tissue underlying the patch after 24 hr showed the presence of not
yet metabolised adenosine corresponding to 13% w/w, compared
with that initially present in the scaffold. The SEM analysis of the
patch explanted at 24 hr shows a surface with the micropatterning
lines only slightly modified (Supporting Information). In addition, in
accordance with histological results, FT‐IR analysis confirmed a good
adhesion of the scaffold to the tissue as evidenced by the presence
FIGURE 3 Analysis of reperfusion injury salvage kinase (RISK) pathway activation: (a, b) western blot analysis of phosphorylated extracellular
signal‐regulated kinase AKT (pAKT) and phosphorylated ERK 1/2 (pERK 1/2) normalised to total AKT and ERK 1/2 proteins and to α‐actinin;
one representative experiment (out of three) per animal is shown; (c, d) quantification of western blots for pAKT and pERK normalised to α‐actinin
and to phosphorylated proteins, detected in the biopsies taken before LAD ligature. SEM of three independent blot quantifications per animal is
shown. Differences exceeding ±3 SEM were considered significant and indicated by coloured arrows. A red arrow indicates AKT phosphorylation
increase after LAD ligature in animal 3_AMI + ADMMP versus 2_AMI + MMP (1.61 vs. 0.94), a green arrow indicates ERK 1/2 phosphorylation
increase after LAD ligature in animal 4_AMI + ADMMP versus 2_AMI + MMP (1.33 versus 0.73), and an orange arrow indicates ERK 1/2
phosphorylation increase 10 min after LAD reopening in animal 4_AMI + ADMMP versus 2_AMI + MMP (1.75 versus 0.69) [Colour figure can be
viewed at wileyonlinelibrary.com]
FIGURE 4 FT‐IR chemical imaging: (a) GAG/protein ratio at the interface with ADMMP in myocardial samples of 3_AMI + ADMMP, (b) GAG/
protein ratio in myocardial samples of 2_AMI + MMP. GAG/protein ratio for (c) control healthy tissue, (d) myocardial tissue of 4_AMI + ADMMP in
the correspondence of the proximal area, and (e) distal area respect to ADMMP position [Colour figure can be viewed at wileyonlinelibrary.com]
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1260 CRISTALLINI ET AL.of typical peaks of the polymeric materials (i.e., ester C═O stretching
at 1,740 cm−1) at the level of the interface with the tissue
(Supporting Information).
After 3 months of follow‐up, HPLC did not detect the presence of
adenosine where ADMMP was implanted and revealed that the patch
was completely degraded. FT‐IR analyses confirmed the absence of
scaffold components, indicating a complete resorption of the material
(Supporting Information).3.5 | Physico‐chemical analysis on myocardial tissue
by means of FT‐IR chemical imaging
The GAG/protein ratio at the interface with the patch was evaluated
in the myocardial samples of 2_AMI + MMP and 3_AMI + ADMMP
and compared with the GAG/protein ratio in a remote area of the
same animal (control; Figure 4a,b). No substantial differences
were found between the GAG/protein ratio for myocardialFIGURE 5 FT‐IR chemical imaging spectra, second derivative spectra, an
control healthy tissue, (b) for myocardial samples of 4_AMI + ADMMP in
ADMMP position [Colour figure can be viewed at wileyonlinelibrary.com]3_AMI + ADMMP samples taken at the level of the proximal
(R = 0.23–0.30) and distal section (R = 0.24‐0.33). These results are
in line with the value obtained from a control area (R = 0.29). As to
2_AMI + MMP myocardial tissue, a significant variability of the
GAG/protein ratio (R = 0.18–0.44), indicative of GAG component
degradation (low values) and interstitial oedema (high values), can be
observed. In Figure 4c–e, the chemical maps of tissues sampled at
proximal and distal level are reported and compared with that of the
control tissue. The mean values measured for the proximal area
(R = 0.23–0.28) and for the distal area (R = 0.23–0.28) are only in
limited domains slightly lower than the one measured for healthy tis-
sue (R = 0.29). This reduction is likely not due to a fibrosis condition
(a process that can last 12 months after the injury) but to the presence
of collagen deposition areas, an event that is part of the normal wound
healing process.
For 4_AMI + ADMMP tissue, CH2/CH3 stretching peak ratio,
GAG/protein ratio, and amide deconvolution were the considered
parameters. The cellularisation of the tissue was evaluated by CH2/d corresponding chemical map: (a) CH2/CH3 stretching peak ratio for
the correspondence of proximal area, and (c) distal area respect to
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second derivative spectra and corresponding chemical maps for a
healthy tissue and for the myocardial tissue of 4_AMI + ADMMP
acquired at both proximal and distal levels are reported. It is important
to state that the CH3 stretching band can be attributed to the
presence of membrane phospholipids, whereas the CH2 stretching
peak derived from glycine and proline residues of collagen. The
CH2/CH3 (2,926 cm
−1/2,956 cm−1) peak ratio can therefore be con-
sidered as indicative of both cellularisation and collagen deposition.
As evidenced by the comparison of ratio values corresponding to
R = 2.45–2.80 for an healthy tissue, R = 2.10–2.45 for tissue at
proximal level, and R = 2.10–2.80 for the tissue at distal level, no
substantial variations in the ratio are observed with respect to the
control tissue, indicating that there is no significant decrease of cellsFIGURE 6 Second derivative spectra acquired from (a) the control of
healthy tissue sections, (b) infarcted area not treated with ADMMP,
and (c) proximal area at the interface with ADMMP in
4_AMI + ADMMP [Colour figure can be viewed at wileyonlinelibrary.
com]and/or increase of collagen in the tissue that was in contact with the
device after 3 months.
In Figure 6, the second derivative spectra are reported, acquired
from the maps of tissue after 3 months of contact with the ADMMP
at proximal level and compared with those acquired from a negative
control (healthy myocardial tissue) and from a positive control
(infarcted tissue). In the spectrum of negative control (Figure 6a), typ-
ical peaks of a healthy tissue can be observed. In Figure 6b, the second
derivative spectrum from a region involved in an infarction process
was reported. Substantial differences are evident respect to the spec-
trum from healthy tissue; in particular, it can be observed a reduction
of intensity of the bands at 1,740–1,720 cm−1, reflecting phagocytosis
of membrane lipids and nucleic acid after infarction. In addition, an
intense absorption of the amide I at 1,643 cm−1, typical of the
infarcted tissue, was revealed. Furthermore, the adsorption at
1,655 cm−1 and at 1,629 cm−1 due to α‐helical and β‐turn protein
structure, respectively, is reduced in infarcted heart tissue.
In Figure 6c, the spectrum of the proximal area at the interface
with the functionalized patch was reported. The main absorption of
amide I at 1,643 cm−1 that appears in the infarcted tissue is not
significant in the area in contact with the device. In addition, the band
at 1,650 cm−1 is more intense than that at 1,655 cm−1, suggesting a
deposition of newly synthesised collagen. Particularly, significant is
the absence, in the proximal area, of the band absorption at
1,638 cm−1, relative to the triple helical structure of collagen in fibrotic
conditions. The presence of bands in the 1,740 to 1,720‐cm−1 range
is highly significant for a good re‐cellularisation of post‐infarction
tissue.4 | DISCUSSION
The present work represents a feasibility study for the employment of
an innovative PLGA/gelatine cardiac patch functionalised wth
adenosine for cardioprotective purposes in a large‐animal model.
On the basis of our previous encouraging results with
microstructured (Cristallini et al., 2014) and multilayer (Cristallini
et al., 2016) patches for stem cell differentiation, the present study
was designed to expand our knowledge on a functionalized
PLGA/gelatine cardiac patch as drug carrier in a large‐animal model
in order to validate the novel paradigm of controlled adenosine
delivery to reduce myocardial reperfusion injury, using a patch able
also to guide the cardiac tissue regeneration.
Physico‐chemical and morphological analyses confirmed the
validity of the used loading method, showing how the assembling of
the scaffold represents an optimal platform for a quick and sustained
release of the cardio‐protective agent. After completion of the drug
reservoir function, reducing the reperfusion injury, the patch can
continue to carry out its second function, which consists in driving
the regenerative processes, as already described in our previous work
(Cristallini et al., 2014; Cristallini et al., 2016).
In vitro and in vivo tests indicate that the amount of adenosine in
the intermediate layer is completely released. In particular, in vivo, at
1262 CRISTALLINI ET AL.24 hr of follow‐up, adenosine was completely released from the patch,
whereas part of the drug was still present in the tissue underneath the
patch and not yet metabolised. Remarkably, the dose of adenosine
that we used, about 11 mg within the myocardial area at risk
(corresponding to about 20 g of myocardium), was concentrated and
present in the tissue for a long time. This dose therefore represents
several times the usual dose (10–12 mg/kg for the entire body) intra-
venously infused for 3 hours (Ross et al., 2005).
A series of advantages for our delivery system can therefore be
considered as compared with direct injection: (a) It allows an early
application of adenosine, which will be present at the moment of
reperfusion when the cardioprotective mechanisms must be already
operative; (b) it does not require a transit in the blood, where the
half‐life of adenosine is very short; (c) it allows to achieve higher
intramyocardial concentrations in a brief period of time and for long
periods when compared with the intravenous infusion, thus limiting
local and systemic adverse effects (eg, it limits the possibility that
adenosine reaches the atrial/nodal tissue where it can alter impulse
genesis/conduction and/or the systemic arterioles thus inducing
hypotension); (d) finally, our system allows adenosine application to
the myocardial tissue even in the absence or limited coronary flow,
and under these circumstances of no‐reflow phenomenon, its biologi-
cal effects could also last much longer than expected.
The biochemical findings suggest that adenosine released from
ADMMP promotes transient RISK pathway activity, including
phospho‐ERK and phospho‐AKT. Several studies have suggested that
an increasing number of agents including adenosine, adipocytokines,
erythropoietin, insulin, natriuretic peptides, and statins, to name a
few, may reduce ischaemia/reperfusion injury via the RISK pathway
activation when administered at the beginning of cardiac reperfusion.
However, the transition to the clinical arena has been fairly successful.
Nevertheless, and despite the controversial results with adenosine,
this endogenous factor resulted superior to other drugs in inducing
cardioprotection in several clinical studies (Niccoli et al., 2013; Singh
et al., 2012). Here, the promising protective effect of very high doses
of adenosine, with no evidences of side effects, is corroborated by the
improvement of other signs and features of the lesion and by the well‐
being of the treated animals.
It has been recently demonstrated that the microscopic morphol-
ogy and the chemical composition of the tissue are particularly rele-
vant for MI progression (Colley, Kazarian, Weinberg, & Lever, 2004;
Yang et al., 2011). In this work, the use of FT‐IR allowed to gather spe-
cific chemical information on different components within an MI site,
discriminating between altered and healthy regions and pointing out
the effects of a patch both loaded with adenosine (ADMMP) and
not loaded (MMP) on the infarcted areas. One important advantage
is the possibility to carry out the analysis without the need of staining
the area of interest, allowing obtaining information about molecular
composition on heterogeneous substrates, such as biological samples
(Yang et al., 2011). Altogether, this and other studies (Gough, Zelinski,
Wiens, Rak, & Dixon, 2003; Liu et al., 1996; Liu et al., 1999;
Samouillan et al., 2017) confirm that FT‐IR chemical analysis can be
used to evaluate pathological changes in MI in a very short time, andthe results are consistent with the infarction fibrosis region shown
with HE staining. The possibility to complement histological and bio-
chemical analyses with the FT‐IR chemical imaging technique
increases the number of investigations while limiting the number of
animals to be employed; this is very important as it impinges upon
the highly desirable accomplishment of the 3Rs (reduce, refine, and
replace) rule in bio‐nanomedicine applications (Accomasso, Cristallini,
& Giachino, 2018).
The histological, histomorphometrical, and FT‐IR analyses carried
out at the level of the tissue/patch interface provided a picture of a
tissue in dynamic conditions, in which normal cardiomyocytes are
associated to the biosynthesis of new collagen and to a less‐fibrotic
outcome of the healing process in hearts treated with functionalised
patches.
Due to the low number of analysed samples, this represents a fea-
sibility study for an innovative and unconventional approach to cardio-
vascular disease, and the clinical implications of these findings will
require further investigation. Concerning the pharmacological aspect,
several groups of drugs with different mechanisms of action might
potentially be targeted to the heart using PLGA/gelatine cardiac
patches (e.g., bradykinin, opioids, insulin‐like growth factor‐1,
transforming growth factor‐β1, cyclosporine A, and nicorandil).
Indeed, a widespread clinical use of these drugs at the required doses
for a cardioprotective response was hampered by the high risk of dan-
gerous side effects. The targeted delivery strategy proposed here may
help to overcome these limitations.
In conclusion, a PLGA/gelatine 3D cardiac patch was
functionalised with adenosine in order to obtain a synergistic effect
between patch cardio‐inductivity and adenosine cardioprotection, a
previously unexplored combination at the basis of a recent interna-
tional patent (PCT/IB2014/0580025). The major finding is that the
functionalisation of bilayered PLGA/gelatine cardiac patches with
adenosine enables its targeted delivery to the ischaemic‐reperfused
area of the heart, where it promotes several beneficial effects. Besides
the activation of pro‐survival signalling pathways, the patch
functionalised with adenosine apparently promotes a more pro-
nounced cellularisation at 24 hr follow‐up and a non‐fibrotic outcome
at 3 months follow‐up.
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Figure S1. a) Optical image of ADMMP after release at 24 h; b) chem-
ical surface map; c) spectra of different surface areas.
Figure S2. SEM image of surface of patch detached from
3_AMI + ADMMP tissue after 24 h of follow‐ up (a); FT‐IR analysis
carried out directly on the 3_AMI + ADMMP tissue at the interface
with the patch: chemical surface map (b); spectra of different surface
areas (c).
Figure S3. FT‐IR Chemical Imaging carried out on the 4_AMI + ADMMP
tissue that was at contact with the device after 3 months: a) Chemical
map of the myocardial tissue; b) Spectrum acquired in the tissue area.
Figure S4. FT‐IR Chemical Imaging a) spectra acquired at three differ-
ent points of the area at the interface with ADMMP, b) spectra
acquired in the region 1800–1500 cm−1 in myocardial samples of
2_AMI + MMP at level of proximal, distal and control areas.
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